A team at the WVU Cancer Institute, led by Dr. Shyam Thakkar, has become the first in the world to commercially implement the FDA-approved 180° C2 Cryoballoon for treating Barrett's esophagus, a precancerous condition that elevates the risk of esophageal cancer. This innovative device, developed by Pentax Medical, offers a novel approach to cancer prevention.
The 180° C2 Cryoballoon facilitates highly targeted cryotherapy, a minimally invasive procedure that precisely freezes and eradicates abnormal cells within the esophagus. This advanced method enhances both safety and precision, marking a significant advancement in the fight against esophageal cancer.
"This new technology offers a significant advancement in how we can eradicate the disease. The ability to precisely target and treat abnormal cells with cryotherapy in this manner offers new possibilities for patients at risk, providing additional safe and effective treatment options," said Dr. Thakkar, director of the Advanced Center of Endoscopy at WVU Medicine and the WVU Cancer Institute. "I am honored to add this tool in our quest of esophageal cancer prevention."
Barrett's Esophagus and the Cryoballoon
Barrett's esophagus is often preceded by years of gastroesophageal reflux disease (GERD). According to the National Institutes of Health, it is found in 5-12% of patients with chronic GERD symptoms. The Pentax Medical Cryoballoon technology marks a significant step forward in endoscopic treatments, enabling physicians to manage complex gastrointestinal conditions more effectively.
Clinical Implementation and Patient Outcomes
The first patient to undergo the procedure, Rickey Harbert, 71, underwent the procedure on October 15th. He was discharged within an hour and experienced a swift recovery. According to Dr. Thakkar, Harbert resumed his normal activities the day following the procedure.
Institutional Commitment
"The WVU Cancer Institute is committed to delivering the highest levels of care, combining cutting-edge research with compassionate treatment," said Dr. Hannah Hazard-Jenkins, executive chair and director of the WVU Cancer Institute. "We are leading the way in cancer care through innovative therapies, groundbreaking clinical trials and a relentless dedication to improving patient outcomes for patients in West Virginia and beyond. In addition to treatment, we are also at the forefront of cancer prevention, using innovative techniques like the Cryoballoon to enhance early detection, thereby preventing progression to cancer in many instances."
